- U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer Eli Lilly and Company
- Eli Lilly’s oral SERD Inluriyo passes muster with FDA in breast cancer Fierce Pharma
- Eli Lilly wins approval of imlunestrant for breast cancer Seeking Alpha
- Recon: RFK Jr. launches review of mifepristone; FDA approves Lilly’s advanced breast cancer drug Regulatory Affairs Professionals Society | RAPS
- Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease The ASCO Post
Source link
